Oruka Therapeutics, Inc. (ORKA) Institutional Ownership

Ownership Summary

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has 141 institutional investors that have filed 13F reports for the period ending December 2025.

• Collectively, these holders controlled 118.5% of Oruka Therapeutics's outstanding shares in December 2025, up from 103.6% in September 2025.
• Their total shares held in ORKA increased 16.32% quarter over quarter, and separately, investors owning Oruka Therapeutics increased 113.64% from a year ago.
• Activity in ORKA broke down as 98 buyers, 18 sellers, and 25 unchanged among 141 total holders.
• Institutional investors collectively held 52.23Mn shares in Oruka Therapeutics as of December 2025, up by 7.33Mn shares quarter on quarter, and up 20.47Mn shares year over year.
• FMR LLC is the top holder of Oruka Therapeutics as of December 31, 2025, with 7.26Mn shares representing 16.48% of outstanding stock.
• Leading buyers of Oruka Therapeutics shares for the quarter ending December 2025 were Paradigm Biocapital Advisors LP (1.71Mn), Remedium Capital Partners, LLC (1.55Mn), BlackRock, Inc. (1.33Mn), State Street Corp (731.82K), VANGUARD GROUP INC (676.86K).
• Leading sellers of Oruka Therapeutics shares for the quarter ending December 2025 were BRAIDWELL LP (1.3Mn), Deep Track Capital, LP (493.27K), Point72 Asset Management, L.P. (437.0K), Affinity Asset Advisors, LLC (156.84K), Franklin Resources Inc (127.36K).
• According to Business Quant data, leading holders of ORKA for December 2025 are FMR LLC (7.26Mn), VR Adviser, LLC (4.15Mn), Fairmount Funds Management LLC (3.71Mn), BlackRock, Inc. (3.54Mn), VIKING GLOBAL INVESTORS LP (2.67Mn), VANGUARD GROUP INC (2.45Mn), Deep Track Capital, LP (2.16Mn), RTW INVESTMENTS, LP (2.06Mn), Commodore Capital LP (1.75Mn), Paradigm Biocapital Advisors LP (1.71Mn).